New strategies for in vivo tissue engineering by mimicry of homing factors for self-endothelialisation of blood contacting materials
Source abstract
Abstract
For years intensive research has been done to endothelialise vascular prostheses with autologous endothelial cells before implantation in patients. However, this procedure is extremely time-, labor- and cost-intensive and can be realized only in very few clinical cases. The discovery of circulating endothelial progenitor cells (EPCs) in 1997 brought new perspectives for the endothelialisation of blood contacting materials. Coating of synthetic graft surfaces with capture molecules for circulating EPCs mimics a pro-homing substrate for fishing out EPCs directly from the bloodstream after implantation. These cells with high proliferation potential can cover the graft with non-thrombogenic endothelium which maintains optimal haemostasis and minimize the risk of restenosis. In this review, different concepts are discussed to capture circulating EPCs on synthetic vascular grafts after implantation. We hypothesize that in vivo self-endothelialisation of blood contacting materials by homing factor-mimetic capture molecules for EPCs may bring revolutionary new perspectives towards future clinical application of stem cell and tissue engineering strategies.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Angiogenesis and VEGF in Cancer · Electrospun Nanofibers in Biomedical Applications · Platelet Disorders and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (96)
Show source-provided references
1. Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors
2. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee
3. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group10.1056/NEJM199812033392304 ↗
4. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators10.1056/NEJM199408253310802 ↗
5. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group10.1056/NEJM199408253310801 ↗
6. New approaches to preventing restenosis10.1136/bmj.327.7409.274 ↗
7. Endothelial progenitor cell therapy for the treatment of coronary disease, acute MI, and pulmonary arterial hypertension: current perspectives
8. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty10.1056/NEJM198703193161201 ↗
9. Silicon carbide-coated stents: clinical experience in coronary lesions with increased thrombotic risk10.1583/1074-6218(1998)005<0032:SCCSCE>2.0.CO;2 ↗
10. Clinical and angiographic outcome after coronary arterial stenting with the carbostent10.1016/S0002-9149(99)00874-7 ↗
11. Multicenter registry to evaluate the efficacy of the NIROYAL stent in de novo or restenotic coronary stenosis
12. Improvements in GORE-TEX vascular graft performance by Carmeda BioActive surface heparin immobilization10.1053/ejvs.2002.1909 ↗
13. Reduction in thrombotic events with heparin-coated Palmaz–Schatz stents in normal porcine coronary arteries10.1161/01.CIR.93.3.423 ↗
14. Small-caliber heparin-coated ePTFE grafts reduce platelet deposition and neointimal hyperplasia in a baboon model10.1016/j.jvs.2004.01.046 ↗
15. Heparin-coated Wiktor stents in human coronary arteries (MENTOR trial). MENTOR Trial Investigators10.1016/S0002-9149(00)00951-6 ↗
16. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study10.1161/01.CIR.103.2.192 ↗
17. Clinical autologous in vitro endothelialization of infrainguinal ePTFE grafts in 100 patients: a 9-year experience10.1016/S0039-6060(99)70025-5 ↗
18. Clinical autologous in vitro endothelialization of 153 infrainguinal ePTFE grafts10.1016/S0003-4975(01)02555-3 ↗
19. Production of extracellular matrix components in tissue-engineered blood vessels10.1089/ten.2006.12.831 ↗
20. In vitro construction of a human blood vessel from cultured vascular cells: a morphologic study10.1016/0741-5214(93)90150-K ↗
21. A completely biological tissue-engineered human blood vessel
22. Functional arteries grown in vitro10.1126/science.284.5413.489 ↗
23. A blood vessel model constructed from collagen and cultured vascular cells10.1126/science.2934816 ↗
24. Human vascular smooth muscle cells and endothelial cells cocultured on polyglycolic acid (70/30) scaffold in tissue engineered vascular graft10.1097/00029330-200708010-00007 ↗
25. Coculture of endothelial and smooth muscle cells on a collagen membrane in the development of a small-diameter vascular graft10.1016/j.biomaterials.2006.11.012 ↗
26. Designer blood vessels and therapeutic revascularization10.1038/sj.bjp.0705457 ↗
27. Technology insight: the evolution of tissue-engineered vascular grafts—from research to clinical practice10.1038/ncpcardio0930 ↗
28. Tissue engineered small-diameter vascular grafts10.1016/S0094-1298(03)00069-5 ↗
29. The daunting quest for a small diameter vascular graft10.1586/17434440.2.6.647 ↗
30. Isolation of putative progenitor endothelial cells for angiogenesis10.1126/science.275.5302.964 ↗
31. How to accelerate the endothelialization of stents
32. Prosthetic vascular grafts: wrong models, wrong questions and no healing10.1016/j.biomaterials.2007.07.017 ↗
33. Endothelial progenitor cells: mobilization, differentiation, and homing10.1161/01.ATV.0000073832.49290.B5 ↗
34. Evidence for circulating bone marrow-derived endothelial cells10.1182/blood.V92.2.362 ↗
35. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells10.1093/emboj/18.14.3964 ↗
36. Effects of granulocyte colony simulating factor on functional activities of endothelial progenitor cells in patients with chronic ischemic heart disease10.1161/01.ATV.0000240248.55172.dd ↗
37. Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis10.1111/j.1537-2995.2006.00985.x ↗
38. Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease10.1161/01.ATV.0000151690.43777.e4 ↗
39. Endothelial progenitor cells: new hope for a broken heart10.1161/01.CIR.0000074242.66719.4A ↗
40. Circulating endothelial cells: life, death, detachment and repair of the endothelial cell layer10.1093/ndt/17.10.1728 ↗
41. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions
42. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells10.1161/01.CIR.0000018166.84319.55 ↗
43. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury10.1161/01.RES.0000083812.30141.74 ↗
44. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy10.1161/01.CIR.0000096490.16596.A6 ↗
45. Human endothelial progenitor cell-seeded hybrid graft: proliferative and antithrombogenic potentials in vitro and fabrication processing10.1089/107632703762687609 ↗
46. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis10.1161/01.ATV.0000114236.77009.06 ↗
47. Working hypothesis to redefine endothelial progenitor cells10.1038/sj.leu.2404676 ↗
48. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood10.1182/blood-2004-04-1396 ↗
49. Origins of circulating endothelial cells and endothelial outgrowth from blood10.1172/JCI8071 ↗
50. Peripheral blood “endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors10.1161/01.CIR.0000058702.69484.A0 ↗
51. Blood monocytes mimic endothelial progenitor cells10.1634/stemcells.2005-0072 ↗
52. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals10.1182/blood-2006-08-043471 ↗
53. Adult endothelial progenitor cells from human peripheral blood maintain monocyte/macrophage function throughout in vitro culture10.1038/sj.cr.7310075 ↗
54. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases10.1161/CIRCULATIONAHA.104.503433 ↗
55. Endothelial-like cells derived from human CD14 positive monocytes10.1046/j.1432-0436.2000.6550287.x ↗
56. Diverse origin and function of cells with endothelial phenotype obtained from adult human blood10.1161/01.RES.0000105569.77539.21 ↗
57. CD34- blood-derived human endothelial cell progenitors10.1634/stemcells.19-4-304 ↗
58. Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like structures in Matrigel under angiogenic conditions10.1016/S0008-6363(00)00270-4 ↗
59. Phenotypic overlap between hematopoietic cells with suggested angioblastic potential and vascular endothelial cells10.1089/152581602753448540 ↗
60. In vitro differentiation characteristics of cultured human mononuclear cells—implications for endothelial progenitor cell biology10.1016/j.bbrc.2005.05.153 ↗
61. Biology of bone marrow-derived endothelial cell precursors10.1152/ajpheart.00662.2006 ↗
62. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice10.1182/blood.V95.11.3289 ↗
63. Arg-Gly-Asp: a versatile cell recognition signal10.1016/0092-8674(86)90259-X ↗
64. Integrin signaling10.1126/science.285.5430.1028 ↗
65. Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion10.1016/S0021-9258(18)45376-8 ↗
66. A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells10.1016/j.jacc.2005.11.081 ↗
67. Capturing circulating endothelial progenitor cells: a new concept tested in the HEALING studies
68. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry10.1016/j.jacc.2005.01.048 ↗
69. Endothelial progenitor cell capture stents—practical use of cell mobilisation
70. Endothelial progenitor cell-coated stents under scrutiny
71. Anonymous
72. In vivo cell seeding with anti-CD34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts10.1161/CIRCULATIONAHA.104.504407 ↗
73. Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo10.1161/01.CIR.0000099501.52718.70 ↗
74. Host bone-marrow cells are a source of donor intimal smooth-muscle-like cells in murine aortic transplant arteriopathy10.1038/89121 ↗
75. Smooth muscle progenitor cells in human blood10.1161/01.CIR.0000031525.61826.A8 ↗
76. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis10.1038/nm0402-403 ↗
77. Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro10.1006/mvre.1999.2171 ↗
78. Mechanisms of hepatocyte growth factor-mediated vascular smooth muscle cell migration10.1161/01.RES.0000102867.54523.7F ↗
79. Endogenous VEGF-A is responsible for mitogenic effects of MCP-1 on vascular smooth muscle cells10.1152/ajpheart.00414.2003 ↗
80. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors10.1182/blood.V95.3.952.003k27_952_958 ↗
81. Use of endothelial cells containing superparamagnetic microspheres to improve endothelial cell delivery to arterial surfaces after angioplasty10.1016/S1051-0443(99)70458-6 ↗
82. Magnetic forces enable rapid endothelialization of synthetic vascular grafts10.1161/CIRCULATIONAHA.105.001446 ↗
83. Magnetically targeted endothelial cell localization in stented vessels10.1016/j.jacc.2006.06.069 ↗
84. Aptamers: an emerging class of molecules that rival antibodies in diagnostics10.1093/clinchem/45.9.1628 ↗
85. Aptamers: an emerging class of therapeutics10.1146/annurev.med.56.062904.144915 ↗
86. Selection of RNA aptamers against recombinant transforming growth factor-beta type III receptor displayed on cell surface10.1016/j.biochi.2006.02.004 ↗
87. Nucleic acid aptamers as tools and drugs: recent developments10.1002/cbic.200300648 ↗
88. Aptamer-based capture molecules as a novel coating strategy to promote cell adhesion10.1111/j.1582-4934.2005.tb00503.x ↗
89. A new technique for the isolation and surface immobilization of mesenchymal stem cells from whole bone marrow using high-specific DNA aptamers10.1634/stemcells.2006-0015 ↗
90. Natural and engineered nucleic acids as tools to explore biology10.1038/nature03195 ↗
91. In vitro selection of RNA molecules that bind specific ligands10.1038/346818a0 ↗
92. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase10.1126/science.2200121 ↗
93. RNA aptamers as reversible antagonists of coagulation factor IXa10.1038/nature00963 ↗
94. Immobilized DNA aptamers used as potent attractors for porcine endothelial precursor cells
95. Blood cell and plasma protein repellent properties of star-PEG-modified surfaces10.1163/156856206778366059 ↗
96. In vitro thrombotic coagulation of the blood: a method for producing a thrombus